EuPOP Life Sciences

EuPOP Life Sciences is a biopharmaceutical company dedicated to developing next-generation vaccines against infectious diseases, cancer, and neurological disorders that address critical unmet medical needs.

The Strategic Synergy

A joint venture between EuBiologics (South Korea) and POP Biotechnologies (USA), EuPOP unites R&D innovation with global commercial strength to develop premium vaccines.

Proprietary Immune Enhancer (EuIMT™) Technology
Extensive experience in Global Vaccine Commercialization
Robust Infrastructure for Large-Scale GMP Production

Proprietary Antigen Display (SNAP™) Platform
Exceptional early-stage R&D capabilities
Strong Network within the U.S. Biotech Ecosystem

Strategic Growth Engine

Synergistic Premium Vaccine Development Powered by EuIMT™ and SNAP™, with Fully Integrated Capabilities from Early R&D to Global Commercialization

Premium Vaccine Pipeline

RSV (Respiratory Syncytial Virus) · HZV (Herpes Zoster) · Padivax (Alzheimer's Disease) & Potential peptide vaccine pipelines

Global Partnerships

Beyond our internal R&D, EuPOP is actively expanding its business scope. We offer flexible partnership models, including co-development of clinical assets and technology out-licensing.